u/enzo_fonseca

identity testing matters more here than purity does

research-use-only material is not approved for human use, and that belongs in every beginner thread

regulatory status varies by jurisdiction and it has moved recently

vendor, compound, batch, service, result — that is the template

Tested three lots over a year rather than three vials from one lot. Cost the same and told me something completely different.

Correction: that is the claimed figure, and the measured one is the higher of the two in your own screenshot.

The hair shedding was the thing that frightened me most and the thing that mattered least. It stopped.

one result is a data point, agreement between two services is evidence

write the concentration on the vial, you will thank yourself

Yes — a proposal with concrete wording gets discussed. A complaint about the rules in general does not.

Disagree with loosening that. The evidence rule is why a supplier report here means something.

Is that a clinical claim or a preclinical one?

no question is too basic here, that is the entire point of the board

Questions about oral contraceptive absorption and gastric emptying are legitimate pharmacology questions with product-specific answers. A pharmacist can answer them properly; a board cannot.

The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.

Cosigning on the no-links rule. It is the only reason the pricing threads are trustworthy.

Chain of custody is why member-funded testing is worth more than a supplied certificate: the vial tested is the vial that arrived at a member’s door.

Chain of custody is why member-funded testing is worth more than a supplied certificate: the vial tested is the vial that arrived at a member’s door.

no question is too basic here, that is the entire point of the board

Anything involving pregnancy, contraception efficacy or fertility planning belongs with a clinician. That is not a disclaimer, it is where the answers actually are.

Sent a vial to Medutest: 97.6% against a claimed 97.5%, with the mass confirming the sequence. Both halves mattered to me.

private prescription pricing moves monthly and the pharmacy is most of the spread

Disagree.

teodor_duarte is right that the two routes are separate. A private prescription does not move you up the list.

Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.

Which paper is that claim from, and was it in humans?

A certificate of analysis is a document describing one batch: what was tested, by what method, and what the result was. Its value depends entirely on whether it names the batch and the method.

Discharge from a specialist service at goal is a normal end point of that pathway. Whether prescribing continues in primary care afterwards is a local decision and is worth asking about at the start rather than at the end.

What did the referral letter actually say?

Agreed — the template exists because a result without the batch and the claim is unanchored.

the price difference between pharmacies this month is genuinely large

Area percent and net peptide content are different measurements and most reports give one. Quote which, or the comparison downstream is meaningless.